OCTOBER 21



Security Simplified

INVESTOR PRESENTATION Q2 & H1FY22

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.



Agenda





Q2FY22 EARNINGS HIGHLIGHTS



Q2FY22 Earnings Highlight






New enterprise customers with more than 500 users added in FY21-22

Quarter	>=500 To <=999	>=1000 To <=4999	>=5000	Grand Total
Q1 FY 2022	08	02	0	10
Q2 FY 2022	18	05	1	24



Company at a glance






Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

Our journey





Over 25 years of simplifying security

Scripting a new success story In the cybersecurity industry




- India's first listed cybersecurity products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Seqrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts and engineers leverages a combination of AI, cloud and patented technologies to deliver timely and advanced protection
- Solutions to secure across platforms

Shareholding Information



Shareholding structure – 30th September 2021



Shareholder Information (as on 30th September 2021)

NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (INR mln)	13,682
% Free-float	27.01%
Free-float market cap (INR mln)	3,696
Total Debt (INR mln)	
Cash & Cash Equivalents (INR mln)	3,166
Shares Outstanding	5.79,02,251
3M ADTV (Shares)*	4,32,204
3M ADTV (INR mln)*	116.7
Industry	IT Software Products

*Source: NSE



INDUSTRY OVERVIEW

NUMBER CROCKER PARTY NUMERAL STREET

10 8 8 10 10

AR DA

Design of the second second

18.87 1 88.81

and and they don't and the light terminant and and the

And Designed to the local division of the lo

-


TE

2021 Cyber threat landscape shows that...




Detection Highlights - Q2 2021* • 1,456 -(\$) 178 243 end detected erected hour ≙ Ø 1,932 1.149 **MINUTES** 11.313 70

*Top seven malware categories features in the chart



...cyber attacks continue to grow in scale and sophistication






Source: IBM

Source: Reputed News Outlets


...and rapid digitization has enhanced need for greater Quick Heal cybersecurity investments



Source: The Ministry of Electronics and Information Technology, TRAI, Government of India, Statista, Google report – Insights for Brands, KPMG Report – Fintech In India, India Data Diviner – Macquarie, Nokia MBIT, Goldman Sachs Investment Research – Portfolio Strategy Research (Sept 19, 2021)



Cyber threat predictions for 2021 and beyond



Source: Segrite Threat Predictions 2021

SEGRITE

Enternrise Outerscourity Colutions by O

Quick Heal

Security Simplified






THE QUICK HEAL ADVANTAGE

Quick Heal is well positioned to leverage its strengths to capture the future opportunities





Strong threat detection and prevention capabilities...

















Cloud Based **Deep Learning Module**



...with State-of-the-Art **Research & Development** leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers

Product **Security Labs Management Team** Detect and analyze Ensures that we build threat vectors across the right products for the globe and provide the right markets at Î₽] advanced protection the right time to customers Incidence Product **Response Team** Development Ensures customers Team are unaffected by Designing & building critical attacks/ cutting edge outages by products & solutions **Research &** responding promptly Development Internet of Things (IOT) **Security Team Ouality** Creating solutions to **Assurance Team** ensure all your connected devices are secure

Product Portfolio – Home, SOHO & Mobile





Robust sales & distribution network in India



Robust pan India coverage Complimentary support from Quick Heal Zonal and regional sales team to engage and support channel

Sales Execution

Landscape across Class B &C towns

Growing presence of T1 distributors across B&C towns. Strong network of T2 resellers - across Class B and Class

Metro Sales Coverage

Strong presence across the top metros in India. Coverage through T1 distributors and T2 resellers


Presence in Class A towns

Strong distribution across Class A towns backed by T2 resellers For details of Sales & support office across India refer annexure (Slide no. 33)

21

QUICK HEAL Global Presence







Committed to deliver exceptional




customer experience

Multi-lingual end user support in English, Hindi and several other major regional Indian languages

2 Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms

3 Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



Experienced Board of Directors





Dr. Kailash Katkar MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi Independent Director

Certified bank forensic accounting professional and anti – money laundering expert





Air Marshal (Retd) Bhushan Nilkanth Gokhale Independent Director

Served on the board of defense PSUs and adviser to government institutions. Appointed as Independent Security Advisor in Ministry of Home Affairs.

Mr. Richard Stiennon Independent Director

Serves as Chief Research Analyst at IT-Harvest, and sits on the advisory boards of several start-ups. Advised boards of global companies like Symantec, McAfee, Cisco, Microsoft and Trend Micro.

...along with strong Management...





Dr. Kailash Katkar MD & CEO

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.



Dr. Sanjay Katkar Joint MD & CTO

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.

...and seasoned Leadership team





Mr. Nitin Kulkarni *CFO*

25+ years of experience in managing different aspects of finance in IT and Manufacturing Industry.

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems.

A member of the Institute of Chartered Accountants of India.



Ms. Reetu Raina *CHRO*

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Sanjay Agrawal CPO

Responsible for driving the overall product vision and strategy in line with market expectations.

Sanjay is an entrepreneurial engineering and product leader with two decades of experience and proven success in building cybersecurity products for the global markets.

A computer engineering graduate from University of Illinois, Sanjay holds a Ph.D. and M.S. from Stanford University in Electrical Engineering and Computer Science (EECS).

...and seasoned Leadership team



Mr. Bibhuti Kar Head, R&D

Responsible for driving company's development efforts leading a team of talented engineering professionals and security researchers.

Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry.

An alumnus of IIT Kharagpur with a master's in ECE, he has worked on missile communication systems with DRDO.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

Over two decades of diverse sales experience including leadership roles in cybersecurity companies.





Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

Over two decades of experience in FMCG, Beverages, Telecom and IT Industries.



Strong brand recognition...

Quick Heal

Technologies

Granted Patent for

its **Signatureless**

Behavior-based

Technology 2019

U.S Patent No. US20170124327A1

Detection

Ouick Heal

Technologies

Granted Patent for

Anti-Ransomware

Technology 2019

US20160378988A1

U.S. Patent No.

Segrite

Endpoint

Security

Certified as **'Top**

business users

by 'AV-Test' in 2020

Product' for

Seqrite Endpoint Security	Seqrite	Quick Heal Technologies	Seqrite
Certified as ' Approved Corporate Endpoint Protection ' for Windows by 'AV-Test' 2018	Best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit 2018	Recognized by NASSCOM's DSCI as 'Cybersecurity Product Pioneer in India' 2019	'Best Performance 2018' award for its Endpoint Security Solution from AV-Test Institute in Germany 2019
Quick Heal Total Security	Seqrite Endpoint Security	Quick Heal	Seqrite Endpoint Security
Certified as 'Top Product' for consumers by 'AV-Test' in 2020	Certified and approved by ICSA Labs in 2020	Best AV of 2020 at the 13th NCN Innovative Product Award 2021	Certified as 'Top Product' for enterprises by AV- Test in 2021





...backed by Certifications, Patents and...

Patented Technologies

USPTO 10,387,649 Signatureless Behaviour-based Detection Technology

USPTO 10,311,234 Anti-Ransomware technology

USPTO 8,973,136 System and method for protecting computer systems from malware attacks

USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

PAIEN

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software

International & ISO Certifications







...CSR initiatives through Quick Heal Foundation

Education

Cyber Shiksha for Cyber Suraksha

2 states2 schools1 college

eRYLA 10000+

Participants from Indonesia, USA, Pakistan, Australia, UAE, Sri Lanka, South Africa, Jamaica

Healthcare

Arogya Yan 6 States, 8 Arogya Yan, 350+ villages

Covid Care Centre

2 covid care centres 1 in association with CYDA First children Covid Care Centre in Pune Consumable donations like masks, surgical gloves, oxyzen concentrator etc.

Vaccination drive in Satara district

Flood relief in Kolhapur Distribution of blanket, satranji, food grains, etc. Lives touched **2 Lakh**+

Lives touched 60000+

2000+ doses administered

Lives touched **42000**+



Quick Heal Academy to drive the next generation of cyber security experts






Popular Courses

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings





Program for Savitribai Phyle Pune University

Savitribai Phule Pune University

Academy Partners

Quantum University

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Guiarat Forensic Sciences University

MoU with Gujarat Forensic Sciences University durina Vibrant Guiarat 2017

Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaians located in Maharashtra

Chitkara University

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program

Deen Daval Upadhvava Colleae

MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi

Disclaimer: Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose




Quick Heal Security Simplified

Q2&H1FY22 EARNINGS


Q2FY22 - Consolidated Performance Highlights






H1FY22 - Consolidated Performance Highlights





Q2FY22 Segment performance






Based on net revenues before adjusting for sales incentives

HIFY22 Segment performance





Q2FY22 - Profitability statement



	S	tandalone		C	onsolidated	
PARTICULARS (₹ mln)	Q2FY21	Q2FY22	% change	Q2FY21	Q2FY22	% change
Total Revenue	828.60	1,037.92	25.26%	844.13	1037.85	22.95%
Direct Cost	33.48	44.29		36.11	44.28	
Gross Profit	795.12	993.63	24.97%	808.02	993.57	22.96%
Gross Margin	95.96%	95.73%	-23bps	95.72%	95.73%	1bps
Operating Cost						
Research and Development (R&D)	168.89	201.02		168.89	201.02	
Sales and Marketing (S&M)	138.28	201.06		142.24	204.14	
General Administration (G&A)	100.62	128.58		106.03	125.33	
Total Expenditure	407.79	530.66	-30.13%	417.16	530.49	-27.17%
EBITDA	387.33	462.97	19.53%	390.86	463.08	18.48%
EBITDA Margin	46.75%	44.61%	-214bps	46.30%	44.62%	-168bps
Depreciation	48.74	41.58		48.79	41.62	
EBIT	338.59	421.39	24.45%	342.07	421.46	23.21%
EBIT Margin	40.86%	40.60%	-26bps	40.52%	40.61%	9bps
Other Income	57.19	36.49		58.25	36.51	
Profit Before Tax (PBT after exceptional item)	395.78	457.88	15.69%	400.32	457.97	14.40%
Тах	111.77	111.40		111.97	111.69	
Profit After Tax (PAT)	284.01	346.48	22.00%	288.35	346.28	20.09%
PAT Margin	34.28%	33.38%	-89bps	34.16%	33.37%	-79bps

HIFY22 – Profitability statement



Total RevenueH1P221H1P22% changeH1P221H1P221H1P221W changeTotal Revenue1,563.001,581.751.20%1,578.751,585.690.44Direct Cost62.4960.7565.1457.91Gross Profit1,500.511,521.001.37%1,513.611,527.780.94Gross Margin96.00%96.16%16bps95.87%96.35%47bOperating Cost8394.78318.50394.78394.78318.50394.78Sales and Marketing (S&M)261.68359.67269.71365.43365.43General Administration (G&A)204.75259.31213.18252.48204.75Total Expenditure784.931,013.76-29.15%801.391,012.69-26.37EBITDA784.9332.07%-1371bps45.11%32.48%-1263bDepreciation95.2482.5495.3082.6020.90EBIT620.34424.70-31.54%616.92432.49-29.90EBIT Margin39.69%26.85%-1284bps39.08%27.27%-1180bOther Income119.8298.84121.4099.02-Profit Before Tax740.16501.90-32.19%738.32531.51-28.01Tax199.82122.81200.39123.40Profit After Tax (PAT)540.34379.09-29.84%537.93408.11-24.13			Standalone			Consolidated	
Direct Cost 62.49 60.75 65.14 57.91 Gross Profit 1,500.51 1,521.00 1.37% 1,513.61 1,527.78 0.94 Gross Margin 96.00% 96.16% 16bps 95.87% 96.35% 47b Operating Cost Research and Development (R&D) 318.50 394.78 318.50 394.78 Sales and Marketing (S&M) 261.68 359.67 269.71 365.43 262.48 Contal Expenditure 784.93 1,013.76 -29.15% 801.39 1,012.69 -26.37 EBITDA 715.58 507.24 -29.11% 712.22 515.09 -27.68 EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263b Depreciation 95.24 82.54 95.30 82.60 -29.90 EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 -21.40 90.02 -29.90 Frofi	PARTICULARS (₹ mln)	H1FY21	H1FY22	% change	H1FY21	H1FY22	% change
Gross Profit Gross Margin1,500.51 96.00%1,521.00 96.16%1.37% 1.518.611,527.78 96.35%0.94 96.35%Operating Cost Research and Development (R&D)318.50394.78318.50394.78318.50394.78Sales and Marketing (S&M)261.68359.67269.71365.43266.87General Administration (G&A)204.75259.31213.18252.48Total Expenditure784.931,013.76-29.15%801.391,012.69-26.37EBITDA715.58507.24-29.11%712.22515.09-27.68EBITDA Margin45.78%32.07%-1371bps45.11%32.48%-1263bDepreciation95.2482.5495.3082.6026.85%-1284bps39.08%27.27%-1180bCother Income119.8298.84-121.4099.02Profit Before Tax740.16501.90-32.19%738.32531.51-28.01Tax199.82122.81200.39123.40Profit After Tax (PAT)540.34379.09-29.84%537.93408.11-24.43	Total Revenue	1,563.00	1,581.75	1.20%	1,578.75	1,585.69	0.44%
Gross Margin 96.00% 96.16% 16bps 95.87% 96.35% 47b Operating Cost Research and Development (R&D) 318.50 394.78 318.50 394.78 318.50 394.78 318.50 394.78 318.50 394.78 365.43 96.35% 47b Sales and Marketing (S&M) 261.68 359.67 269.71 365.43 96.35% 4269.71 365.43 96.35% 4269.71 365.43 96.35% 4269.71 365.43 96.35% 4269.71 365.43 96.35% 4269.71 365.43 96.35% 4269.71 365.43 95.30 45.48 427.83 1.013.76 -29.15% 801.39 1.012.69 -27.68 412.48 -126.39 -27.68 412.49 -27.68 412.49 42.48% -126.39 -28.48 -126.39 -28.48 -29.90 45.48 42.49 42.49 432.49 -29.90 45.48 42.470 -31.54% 616.92 432.49 -29.90 45.48 42.470 -31.54% 616.92 432.49	Direct Cost	62.49	60.75		65.14	57.91	
Operating Cost 318.50 394.78 318.50 394.78 Research and Development (R&D) 318.50 394.78 318.50 394.78 Sales and Marketing (S&M) 261.68 359.67 269.71 365.43 General Administration (G&A) 204.75 259.31 213.18 252.48 Total Expenditure 784.93 1,013.76 -29.15% 801.39 1,012.69 -26.37 EBITDA 715.58 507.24 -29.11% 712.22 515.09 -27.68 EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263b Depreciation 95.24 82.54 95.30 82.60 -29.90 EBIT 620.34 424.70 -31.54% 616.92 432.49 -29.90 EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 121.40 99.02 - Profit Before Tax 740.16 523.54 -29.27%	Gross Profit	1,500.51	1,521.00	1.37%	1,513.61	1,527.78	0.94%
Research and Development (R&D) 318.50 394.78 318.50 394.78 Sales and Marketing (S&M) 261.68 359.67 269.71 365.43 General Administration (G&A) 204.75 259.31 213.18 252.48 Total Expenditure 784.93 1,013.76 -29.15% 801.39 1,012.69 -26.37 EBITDA 715.58 507.24 -29.11% 712.22 515.09 -27.68 EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263b Depreciation 95.24 82.54 95.30 82.60 -29.90 EBIT 620.34 424.70 -31.54% 616.92 432.49 -29.90 EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 121.40 99.02 -27.68 Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Exceptional items - 21.64 - - - - - <td>Gross Margin</td> <td>96.00%</td> <td>96.16%</td> <td>16bps</td> <td>95.87%</td> <td>96.35%</td> <td>47bps</td>	Gross Margin	96.00%	96.16%	16bps	95.87%	96.35%	47bps
Sales and Marketing (S&M) 261.68 359.67 269.71 365.43 General Administration (G&A) 204.75 259.31 213.18 252.48 Total Expenditure 784.93 1,013.76 -29.15% 801.39 1,012.69 -26.37 EBITDA 715.58 507.24 -29.11% 712.22 515.09 -27.68 EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263 b Depreciation 95.24 82.54 95.30 82.60 -29.90 EBIT Margin 6620.34 424.70 -31.54% 616.92 432.49 -29.90 EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180 b Other Income 119.82 98.84 121.40 99.02 - - Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Exceptional items - 21.64 - - - - Profit Before Tax 740.16 501.90 -32.19% 738.32	Operating Cost						
General Administration (G&A) 204.75 259.31 213.18 252.48 Total Expenditure 784.93 1,013.76 -29.15% 801.39 1,012.69 -26.37 EBITDA 715.58 507.24 -29.11% 712.22 515.09 -27.68 EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263b Depreciation 95.24 82.54 95.30 82.60 -29.90 EBIT Margin 660.34 424.70 -31.54% 616.92 432.49 -29.90 EBIT Margin 99.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 121.40 99.02 -29.90 Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Fax 740.16 501.90 -32.19% 738.32 531.51 -28.01 Profit Before Tax 740.16 501.90 -32.19% 738.32 531.51 -28.01 Fax 199.82 122.81 200.39	Research and Development (R&D)	318.50	394.78		318.50	394.78	
Total Expenditure784.931,013.76-29.15%801.391,012.69-26.37EBITDA715.58507.24-29.11%712.22515.09-27.68EBITDA Margin45.78%32.07%-1371bps45.11%32.48%-1263bDepreciation95.2482.5495.3082.6080.13982.60EBIT6620.34424.70-31.54%616.92432.49-29.90EBITMargin39.69%26.85%-1284bps39.08%27.27%-1180bOther Income119.8298.84121.4099.02-27.68Profit Before Tax (PBT after exceptional items)740.16523.54-29.27%738.32531.51-28.01Tax19.82121.64Profit Before Tax (PAT)540.34379.09-29.84%537.93408.11-24.13	Sales and Marketing (S&M)	261.68	359.67		269.71	365.43	
EBITDA 715.58 507.24 -29.11% 712.22 515.09 -27.68 EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263b Depreciation 95.24 82.54 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 95.30 82.60 99.02 90.02	General Administration (G&A)	204.75	259.31		213.18	252.48	
EBITDA Margin 45.78% 32.07% -1371bps 45.11% 32.48% -1263b Depreciation 95.24 82.54 95.30 82.60 95.30 82.69 95.30 95.90 95.90 95.90 95.90 95.90 95.90 95.90 95.90 95.90 95.90 95.90 95.90 99.90 99.90 99.90 99.90 99.90 99.90 99.90 99.90 99.90 99.90 99.90 99.90 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 95.91 <td< td=""><td>Total Expenditure</td><td>784.93</td><td>1,013.76</td><td>-29.15%</td><td>801.39</td><td>1,012.69</td><td>-26.37%</td></td<>	Total Expenditure	784.93	1,013.76	-29.15%	801.39	1,012.69	-26.37%
Depreciation 95.24 82.54 95.30 82.60 EBIT 620.34 424.70 -31.54% 616.92 432.49 -29.90 EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 -121.40 99.02 - Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Exceptional items - 21.64 - - - - Profit Before Tax (PBT after exceptional items) 740.16 501.90 -32.19% 738.32 531.51 -28.01 Exceptional items - 21.64 - - - - - Profit Before Tax 740.16 501.90 -32.19% 738.32 531.51 -28.01 Tax 199.82 122.81 200.39 123.40 - Profit After Tax (PAT) 540.34 379.09 -29.84% 537.93 408.11 -24	EBITDA	715.58	507.24	-29.11%	712.22	515.09	-27.68%
EBIT 620.34 424.70 -31.54% 616.92 432.49 -29.90 EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 -29.27% 738.32 531.51 -28.01 Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Exceptional items - 21.64 -	EBITDA Margin	45.78%	32.07%	-1371bps	45.11%	32.48%	-1263bps
EBIT Margin 39.69% 26.85% -1284bps 39.08% 27.27% -1180b Other Income 119.82 98.84 121.40 99.02 <td< td=""><td>Depreciation</td><td>95.24</td><td>82.54</td><td></td><td>95.30</td><td>82.60</td><td></td></td<>	Depreciation	95.24	82.54		95.30	82.60	
Other Income 119.82 98.84 121.40 99.02 Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Exceptional items - 21.64 - - - - Profit Before Tax 740.16 501.90 -32.19% 738.32 531.51 -28.01 Tax 199.82 122.81 200.39 123.40 - Profit After Tax (PAT) 540.34 379.09 -29.84% 537.93 408.11 -24.13	EBIT	620.34	424.70	-31.54%	616.92	432.49	-29.90%
Profit Before Tax (PBT after exceptional items) 740.16 523.54 -29.27% 738.32 531.51 -28.01 Exceptional items - 21.64 -	EBIT Margin	39.69%	26.85%	-1284bps	39.08%	27.27%	-1180bps
Exceptional items - 21.64 - - Profit Before Tax 740.16 501.90 -32.19% 738.32 531.51 -28.01 Tax 199.82 122.81 200.39 123.40 Profit After Tax (PAT) 540.34 379.09 -29.84% 537.93 408.11 -24.13	Other Income	119.82	98.84		121.40	99.02	
Profit Before Tax 740.16 501.90 -32.19% 738.32 531.51 -28.01 Tax 199.82 122.81 200.39 123.40 Profit After Tax (PAT) 540.34 379.09 -29.84% 537.93 408.11 -24.13	Profit Before Tax (PBT after exceptional items)	740.16	523.54	-29.27%	738.32	531.51	-28.01%
Tax 199.82 122.81 200.39 123.40 Profit After Tax (PAT) 540.34 379.09 -29.84% 537.93 408.11 -24.13	Exceptional items	-	21.64		-	-	
Profit After Tax (PAT) 540.34 379.09 -29.84% 537.93 408.11 -24.13	Profit Before Tax	740.16	501.90	-32.19%	738.32	531.51	-28.01%
	Тах	199.82	122.81		200.39	123.40	
PAT Margin 34.57% 23.97% -1060bps 34.07% 25.74% -834h	Profit After Tax (PAT)	540.34	379.09	-29.84%	537.93	408.11	-24.13%
	PAT Margin	34.57%	23.97%	-1060bps	34.07%	25.74%	-834bps

NOTE: Certain figures have been re-grouped wherever necessary



	Stand	lalone	Consolidated		
In %	Q2FY21	Q2FY22	Q2FY21	Q2FY22	
Expenses					
Direct Cost / Revenue	4.04%	4.27%	4.28%	4.27%	
R&D / Revenue	20.38%	19.37%	20.01%	19.37%	
S&M / Revenue	16.69%	19.37%	16.85%	19.67%	
G&A / Revenue	12.14%	12.39%	12.56%	12.08%	
Total Cost / Revenue	49.21%	51.13%	49.42%	51.11%	
Margin					
Gross Margin	95.96%	95.73%	95.72%	95.73%	
EBITDA	46.75%	44.61%	46.30%	44.62%	
EBIT	40.86%	40.60%	40.52%	40.61%	
PBT	47.76%	44.12%	47.42%	44.13%	
PAT	34.28%	33.38%	34.16%	33.37%	



	Standa	alone	Consolidated		
In %	H1FY21	H1FY22	H1FY21	H1FY22	
Expenses					
Direct Cost / Revenue	4.00%	3.84%	4.13%	3.65%	
R&D / Revenue	20.38%	24.96%	20.17%	24.90%	
S&M / Revenue	16.74%	22.74%	17.08%	23.05%	
G&A / Revenue	13.10%	16.39%	13.50%	15.92%	
Total Cost / Revenue	50.22%	64.09%	50.76%	63.86%	
Margin					
Gross Margin	96.00%	96.16%	95.87%	96.35%	
EBITDA	45.78%	32.07%	45.11%	32.48%	
EBIT	39.69%	26.85%	39.08%	27.27%	
PBT	47.36%	33.10%	46.77%	33.52%	
PAT	34.57%	23.97%	34.07%	25.74%	

Consolidated Balance Sheet

					1
EQUITY AND LIABILITIES ([₹] mln)	Sep 30, 2020	Sep 30, 2021	ASSETS ([₹] mln)	Sep 30, 2020	Sep 30, 2021
Share Holder's Funds:			Non-Current Assets:		
Equity Share Capital	642.03	579.01	Property, plant and equipment	1,427.40	1,361.70
Share application money pending			Capital work-in-progress	34.00	21.10
allotment	-	0.03	Intangible assets	70.86	43.63
Reserves and Surplus	6,341.20	5,205.94	Non-current financial assets		
Total Shareholder Funds	6,983.23	5,784.98	Investments in MF ,Tax-Free Bonds & others	172.78	247.48
Non-Current Liabilities	0,903.23	3,704.90	Loan and Security Deposits	3.82	3.65
			Bank Balances	4.03	-
Net employee defined benefit liabilities	6.86	2.03	Deferred tax assets (net)	31.16	-
Other Non Current Liabilities	0.30	-	Other non current assets	211.23	129.46
Deferred tax liability (net)	-	6.14	Total Non-Current Assets	1,955.28	1,807.02
Total Non-Current Liabilities	7.16	8.17	Current assets:		
	7.10	0.17	Inventories	46.69	36.83
Current Liabilities:			Investment in Mutual Fund	3,658.79	2,542.88
Trade and Other Payables	501.73	500.02	Trade and other receivables	1,327.97	1,469.35
Other Financial Liabilities	18.15	12.22	Bank Balances & Cash and Cash Equivalents	128.09	158.12
Other Current Liabilities	142.54	172.98	Investment in Fixed Deposit	561.50	406.80
Net employee defined benefit liabilities	11.42	13.75	Loan and security deposits	8.03	3.93
Current tax liabilities (Net)	136.97	1.62	Interest accrued on FDR & Tax-Free Bonds	12.77	5.46
			Other Current assets	102.08	57.81
Total Current Liabilities	810.81	700.59	Assets classified as held for sale	-	5.54
Total Equity & Liabilities	7,801.20	6,493.74	Total Current Assets	5,845.92	4,686.72
NOTE: Certain figures have been re-grouped w	nerever necessary		Total Assets	7,801.20	6,493.74

NOTE: Certain figures have been re-grouped wherever necessary



Standalone Balance Sheet

EQUITY AND LIABILITIES (₹ mln)

Share application money pending

Net employee defined benefit liabilities

Net employee defined benefit liabilities

Share Holder's Funds:

Equity Share Capital

Reserves and Surplus

Total Shareholder Funds

Other Non Current Liabilities

Total Non-Current Liabilities

Deferred tax liability (net)

Trade and Other Payables

Other Financial Liabilities

Other Current Liabilities

Current tax liabilities (Net)

Total Current Liabilities

Total Equity & Liabilities

Current Liabilities:

Non-Current Liabilities

allotment

		_	Security Simplified	Enterprise Cybersecurity Solutions by
Sep 30, 2020 S	5ep 30, 2021	ASSETS ([₹] mln)	Sep 30, 2020	Sep 30, 2021
		Non-Current Assets:		
642.03	579.01	Property, plant and equipment	1,427.18	1,361.33
042.05	575.01	Capital work-in-progress	34.00	21.10
-	0.03	Intangible assets	70.68	43.49
6,387.57	5,220.84	Non-current financial assets		
· ·		Investments in MF ,Tax-Free Bonds & others	287.79	348.12
7,029.60	5,799.88	Loan and Security Deposits	3.82	3.65
		Bank Balances	4.03	
6.86	2.03	Deferred tax assets (net)	31.16	-
0.30	-	Other non current assets	211.23	129.46
-	6.14	Total Non-Current Assets	2,069.89	1,907.15
7.46		Current assets:		
7.16	8.17	Inventories	46.47	36.80
		Investment in Mutual Fund	3,658.79	2,542.88
500.29	503.55	Trade and other receivables	1,315.42	1,475.03
18.15	12.22	Bank Balances & Cash and Cash Equivalents	68.73	70.86
140.07	171.94	Investment in Fixed Deposit	561.50	406.80
11.42	13.75	Loan and security deposits	7.96	3.86
136.37	1.21	Interest accrued on FDR & Tax-Free Bonds	12.77	5.46
		Other Current assets	101.53	56.34
806.30	702.67	Assets classified as held for sale	-	5.54
7,843.06	6,510.72	Total Current Assets	5,773.17	4,603.57
herever necessary		Total Assets	7,843.06	6,510.72

Quick Heal

SEG

TE

NOTE: Certain figures have been re-grouped wherever necessary

Working capital analysis



159 4 54 3 5 150 50 141 53 109 104 93 Receivable Inventory Payable Net Working Receivable Inventory Payable Net Working Receivable Inventory Payable Net Working Capital Days **Capital Days** Days Capital Days Days Days Days Days Days Days Days Days

At the end of September, 2020*

At the end of March, 2021**

At the end of September, 2021*

Note*

Receivable Days = [(Debtors/ Sales) X (183 days)] Inventory Days = [(Inventory/Sales) X (183 days)] Payable Days = [(Creditor/Sales) X (183 days)]

Note**


Receivable Days = [(Debtors/ Sales) X (365 days)] Inventory Days = [(Inventory/Sales) X (365 days)] Payable Days = [(Creditor/Sales) X (365 days)]

Calculation is based on net revenues before adjusting for sales incentives

Return ratio analysis

Return on Capital Employed*





Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

RoCE = EBIT / Avg. Capital Employed (Equity + Debt)

Cash Adj. RoCE = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

ROE = PAT / Avg. Equity

Return on Equity*

* Calculated on trailing 12 months basis





Thank You

Chief Financial Officer

Mr. Nitin Kulkarni Nitin.Kulkarni@quickheal.co.in +91-20-66813232

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408 www.quickheal.co.in

Annexure

Products Sold in following countries

- Australia
- Banaladesh
- Benin
- Cambodia
- Canada
- Chile
- Colombia
- Congo
- Ecuador
- El Salvador
- France
- Gambia

- - Guinea
- Italy
- Japan

- Germany
- Honduras
- Hong Kong
- Jordan • Kenva
- Kuwait
- Macao
- Malaysia
 - Mauritius

- Paraauav
- Peru

Mexico

Niaeria

Morocco

Netherlands

New Zealand

Saudi Arabia

Solomon Islands

Singapore

South Africa

South Korea

Sri Lanka

Panama

- Philippines
- Qatar
- Rwanda
- Thailand
- Turkev
- Uganda
- UAE
- USA
 - Venezuela

Sales & Support offices across India

- Chandiaarh
- New Delhi
- Jaipur .
- Lucknow
- Patna •
- Guwahati
- Ahmedabad
- Indore
- Surat
- Nashik
- Nagpur

- Mumbai
- Pune
- Aurangabad
- Kolhapur
- Raipur
- Kolkata
- Bhubaneshwar
- Hyderabad
- Bangalore
- Chennai
- Kochi



